Welcome to the ResusX:Podcast. Each episode features an amazing talk from the ResusX conference. This is a podcast dedicated to your sickest patients, and it's all FOAMed. For more great content, including our monthly grand rounds, newsletter, and more go to www.ResusX.com now.
ResusX:Podcast
Claim This Podcastby Haney Mallemat
5.0(23 reviews)
160 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇬🇧
56
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality79
Social0
YouTube0
Engagement85
Podcast Overview
Welcome to the ResusX:Podcast. Each episode features an amazing talk from the ResusX conference. This is a podcast dedicated to your sickest patients, and it's all FOAMed. For more great content, including our monthly grand rounds, newsletter, and more go to www.ResusX.com now.
Language
🇺🇲
Publishing Since
4/9/2023
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
56
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality79
Social0
YouTube0
Engagement85
8
Excellent Areas
0
Good Performance
11
Growth Opportunities
excellent
Publishing Consistency
Every 6 days
Performing excellently!
poor
Episode Thumbnails
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for ResusX:Podcast
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
February 13, 2026
Cytokine storm in acute respiratory distress syndrome
<p>Is the "Cytokine Storm" the Real Killer in ARDS?<br><br> When a localized lung injury spirals into a systemic catastrophe, we call it a cytokine storm—but are we actually any closer to stopping it, or are we just watching the rain? This deep-dive review, published in the Journal of Intensive Medicine, synthesizes decades of mechanistic research and clinical trials to map how dysregulated immune pathways bridge the gap between respiratory failure and multiorgan dysfunction syndrome (MODS). The authors break down the biological chaos of ARDS into two distinct camps: the hyperinflammatory and hypoinflammatory subphenotypes. While the former is defined by a "reactive" profile of elevated IL-6, IL-8, and sTNFr-1, it’s not just about the numbers; it’s about the "so what" at the bedside. These profiles dictate who survives, who stays on the vent, and critically, who actually responds to interventions like higher PEEP or corticosteroids. We move beyond standard supportive care to explore the cutting edge of precision medicine. From the established success of the DEXA-ARDS trial to the emerging potential of cytokine nanosponges and MSC-derived extracellular vesicles, this episode explores how we can shift from "one-size-fits-all" ventilation to biomarker-guided, disease-modifying therapy. Ready to move past the Berlin Definition and into the era of personalized intensive care? Tune in as we untangle the storm.</p>
February 4, 2026
Diuretic resistance in cardiorenal syndrome: mechanisms, monitoring and phenotype-tailored management
<p><strong>Can we break the cycle of Diuretic Resistance?</strong></p> <p>What do you do when the "gold standard" treatment for your congested patient simply stops working? Diuretic resistance (DR) affects up to one-third of patients with heart failure, turning a routine clinical task into a high-stakes battle against prolonged hospitalization and mortality. In this episode, we dive into a comprehensive narrative review that moves beyond simple drug escalation to offer a sophisticated, phenotype-driven roadmap for the modern clinician. The authors synthesize data from nearly 100 pivotal studies to dismantle the "one-size-fits-all" approach to decongestion. We explore the multifactorial drivers of resistance—from chloride depletion and neurohormonal "braking" to the structural remodeling of the nephron itself. Rather than just pushing more furosemide, the study highlights how early monitoring of urinary sodium and the use of point-of-care ultrasound (POCUS) can identify failure before it becomes entrenched. The real "so what" for your next shift lies in the study’s focus on four challenging phenotypes: Right Heart Failure, advanced CKD, Obesity, and Frailty. We discuss why chloride repletion might be your secret weapon, how metabolic therapies like GLP-1 RAs are changing the game for obese patients, and why a small rise in creatinine shouldn't always scare you away from aggressive diuresis. Tune in to learn how to tailor your decongestion strategy to the patient in front of you and finally get ahead of the curve on diuretic resistance.</p>
January 29, 2026
Efficacy and safety of anticoagulant therapy in sepsis: A systematic review and meta-analysis
<p><strong>Sepsis and Coagulation: Is It Time to Put the Heparin Away?</strong></p> <p>Is "thinning the blood" the missing piece in the sepsis puzzle, or just a recipe for disaster? Sepsis triggers a deadly cascade of inflammation and clotting, yet the debate over therapeutic anticoagulation has left ICU clinicians caught between the potential for organ salvage and the perilous risk of hemorrhage. In this episode, we break down a 2026 systematic review and meta-analysis from the *Journal of International Medical Research*. The investigators pooled data from 10 major studies—including 8 randomized controlled trials—covering nearly 7,500 adult patients to determine if agents like heparin, antithrombin III, or recombinant thrombomodulin actually save lives. The verdict? We discuss why the data shows that routine anticoagulation in unselected sepsis patients offers **no significant mortality benefit** and trends toward a higher risk of major bleeding. We also unpack a critical discrepancy: while observational studies suggested a survival advantage, the rigorous RCTs flatly contradicted this, exposing the dangers of selection bias. Join us as we explore why the "one-size-fits-all" approach to sepsis anticoagulation is officially dead and why future hopes now rest entirely on high-risk subgroups like those with disseminated intravascular coagulation (DIC). Tune in to get the evidence you need to make safer decisions at the bedside.</p>
160 total episodes available
Similar Podcasts
Discover related shows you might enjoy
EMCrit FOAM Feed
Scott D. Weingart, MD FCCM
Critical Care Time
Critical Care Time Podcast
Critical Care Scenarios
Brandon Oto, PA-C, FCCM and Bryan Boling, DNP, ACNP, FCCM
Emergency Medicine Cases
Dr. Anton Helman
Alert Medic 1 - Podcast
Alert Medic 1
Emergency Medical Minute
Emergency Medical Minute
Coffee Break HEMS Podcast
Austin Kiser
The World’s Okayest Medic Podcast
Mike Carunchio
The FlightBridgeED Podcast
Long Pause Media | FlightBridgeED
EMS 20/20
Long Pause Media | FlightBridgeED
The Resus Room
Simon Laing, Rob Fenwick & James Yates
Core IM | Internal Medicine Podcast
Core IM Team
Core EM - Emergency Medicine Podcast
Core EM
The Critical Care Commute Podcast
Critical Care Commute
PulmPEEPs
PulmPEEPs
Deep-dive analytics for ResusX:Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is ResusX:Podcast?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 7 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.